We are (4-([1,1-biphenyl]-4-yl(phenyl)amino)phenyl)boronic acid CAS:1084334-86-0 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Related News: Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.2,5-Difluoronitrobenzene The quality of the drug substance determines the quality of the preparation, so its quality standards are very strict. Countries around the world have formulated strict national pharmacopoeia standards and quality control methods for their widely used drug substances.N,N'-(4,6-Dichloropyrimidine-2,5-diyl)diformamide CAS:116477-30-6 In the context of the new medicine policy, with the development of China’s R & D strength, the number of innovative drugs approved has been blown out, which further strengthened the demand and speed of industrialization of raw materials in China.6139-83-9 The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.